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Background: The incidence of non-alcoholic steatohepatitis (NASH) is increasing worldwide and a poorly defined
subset of patients develops end-stage liver disease and hepatocellular carcinoma (HCC). Differences in the biological
behaviour, tumour characteristics, associated risk factors, treatment outcomes and overall survival of patients with
NASH-HCC remain poorly defined. The aim of this study was to determine and analyze these differences in a large
clinical cohort to guide treatment decisions.
Methods: 1119 patients with HCC treated in an 11 year period at the University Medical Centre of the Johannes
Gutenberg University Mainz were retrospectively analyzed.
Results: Patients with NASH-HCC (n = 45) were older (67.6 vs. 65 years), had an increased frequency of the metabolic
syndrome and complications with a higher incidence of obesity (31.1% vs. 14.7%), type II diabetes mellitus (66.7% vs. 37.85%),
a higher rate of myocardial infarction (13.3% vs. 4.8%) and apoplectic stroke (8.9% vs. 2.1%) (all p < 0.05). Interestingly,
liver function was preserved to a higher extent and MELD scores were significantly lower in NASH-HCC. Nonetheless,
resection or orthotopic liver transplantation was performed only in 17.8% and 4.4% of NASH-HCC respectively. Overall
survival was lower compared to HCC of other aetiologies. Independent of the underlying aetiology BMI exhibited a
positive correlation with overall survival.
Conclusion: Despite retained liver function, patients with NASH-associated HCC showed a decreased overall survival.
With regards to the expected increasing prevalence of NASH, it will be necessary to improve screening and surveillance
strategies to identify HCC in NASH early and improve survival.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer-
related deaths worldwide [1]. Globally the majority of
HCC are associated with chronic viral hepatitis with a
high prevalence in less industrialized countries mainly
East Asia and sub-Saharan Africa. Over the last years,
the incidence of HCC in these countries is decreasing
while the incidence of HCC in developed countries has
increased [1,2]. This trend is likely related to the increas-
ing prevalence of the metabolic syndrome and the* Correspondence: schatten@uni-mainz.de
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unless otherwise stated.associated risk factors including insulin resistance and
obesity [3]. These risk factors contribute to the develop-
ment of non-alcoholic fatty liver disease (NAFLD) which
has become the most prevalent liver disease world-wide
[4]. The clinical spectrum of NAFLD ranges from iso-
lated hepatic steatosis to non-alcoholic steatohepatitis
(NASH), which is characterized by hepatic necroinflam-
mation and varying degrees of fibrosis [5]. The estimated
prevalence of NAFLD in the adult population ranges
from 9-37% with strong cultural and geographic differ-
ences and the prevalence of NASH is estimated at 3-5%
[6]. Although epidemiological studies have to determine
the risk of disease progression, it has become obvious
that chronic inflammation in NASH is a trigger that can
lead to the development of HCC – even in the absence
of cirrhosis in a yet poorly defined subset of patients [7].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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overall prognosis is poor with a 5-year-survival rate of
15% [8]. Treatment decisions for HCC are commonly
based on the Barcelona Clinic Liver Cancer (BCLC) sta-
ging system which considers performance status, tumour
size and location, extra hepatic spread and the underlying
liver function [9]. For the multimodal treatment of HCC
different surgical, interventional (radiological/sonographi-
cal) and non-interventional procedures have been estab-
lished. Curative treatment options include resection,
orthotopic liver transplantation (OLT) or locoregional
therapies and are available for early tumour stages. For
intermediate tumour stages (BCLC B), transarterial che-
moembolization (TACE) with or without drug-eluting
beads (DEB-TACE) and selective internal radiation ther-
apy (SIRT) are used. In advanced tumour stages (BCLC C)
systemic therapy with the multikinase inhibitor sorafenib
represents the current standard in patients with compen-
sated cirrhosis [10]. Best supportive care is recommended
for end-stage HCC patients (BCLC D) [11].
The global increase of metabolic risk factors including
diabetes and obesity will lead to an increasing prevalence
of NASH and complications including cirrhosis and
HCC [7]. Currently only few studies have explored dis-
ease characteristics, treatment and outcome of NASH-
related HCC. The aim of this retrospective analysis was
to evaluate differences in the epidemiology, risk factors,
tumour characteristics, therapy and overall survival in
patients with NASH-HCC in contrast to non-NASH ae-
tiologies in a European cohort over a period of 11 years.
Methods
Patient characteristics
Patients with HCC who were referred to the University
Medical Centre of the Johannes Gutenberg University
Mainz between January 2000 and December 2010 were
included in a clinical database after informed consent
was given and analyses were performed retrospectively.
The diagnosis of HCC was made according to the
AASLD/EASL criteria [12]. All patients were classified
according to the tumour node metastasis staging system
of the UICC [13] and the stage of HCC was described
according to BCLC-classification [12]. Survival data were
acquired from clinical records or by contacting registra-
tion offices. Tumor-specific treatment and survival times
were extracted from patient records. Diabetes mellitus,
hypertension, hyperlipidemia and the metabolic syn-
drome were defined according to the definitions of the
Joint Scientific Statement for Harmonizing the Meta-
bolic Syndrome [14]. Laboratory results were obtained
at the time of initial diagnosis of HCC and were consid-
ered missing if not available within a maximum of
90 days. Liver cirrhosis was determined based on histo-
logical features or clinical signs including ascites, hepaticencephalopathy, thrombocytopenia, splenomegaly, labora-
tory results indicating impaired liver function. NASH was
defined according to the histological features of NASH,
when biopsy results were available. Cryptogenic cirrhosis
in the presence of metabolic risk factors and in the ab-
sence of significant alcohol consumption was considered
as NASH as previously established [15].
Ethical consideration
This study was carried out in compliance with the
Helsinki Declaration (http://www.wma.net/en/30publica
tions/10policies/b3/index.html). No formal ethics ap-
proval was required for this strictly retrospective study as
was ruled by the local ethics committee (Ethik-Kommission
der Landesärztekammer Rheinland-Pfalz).
Data analyses and statistics
Data are given as median and range for numeric variables,
or as counts and percentages for categorical variables. For
statistical evaluation continuous variables are compared
between groups of patients by the Mann–Whitney U test;
categorical variables are compared using Fisher exact test
or its equivalent for more than 2 categories. All calcula-
tions were done with R version 3.0.2. A p-value below
0.05 was considered significant.
Results
Clinical characteristic and complications of the metabolic
syndrome in NASH-HCC
A total of 1119 patients with HCC were included between
2000 and 2010 for further analysis. The median age for
the entire cohort was 65.1 years (range 15.3-89.9), of
which 82.6% (n = 924) were male and 98.3% (n = 1100) of
Caucasian origin. Chronic viral hepatitis was the most fre-
quent underlying cause of HCC (HBV 12.1%, HCV
22.7%), followed by alcohol-induced liver disease in 36%.
In 17% of patients HCC developed in cryptogenic liver dis-
ease. Histological or morphologically confirmed NASH was
identified in 4% (n = 45), which was validated by liver hist-
ology and after exclusion of significant alcohol consump-
tion. Aetiologies of HCC are pictured in Figure 1. Baseline
patient characteristics are summarized in Table 1. Patients
with NASH-HCC were significant older (median age 67.6
versus 65 years, respectively; p = 0.007) and exhibited a
lower predominance of male gender compared to non-
NASH-HCC (77.8% (n = 35) vs. 82.7% (n = 888), p = 0.820).
The NASH-HCC group was defined by higher BMI and
average BMI in NASH-HCC was (median [range]) 29
[19.4-49.6] kg/m2 vs. 26.6 [16.5-48.4] kg/m2; p = 0.022.
Additionally, patients with NASH-HCC exhibited a higher
prevalence of type 2 diabetes mellitus (66.7% vs. 37.8%,
p = 0.024) and had a trend towards arterial hypertension
(71.1% vs. 45.2%, p = 0.060). The rate of cardiovascular
complications such as myocardial infarction (13.3% (n = 6)
Figure 1 Aetiologies of HCC. Aetiologies of HCC in 1119 patients between 2000 and 2010.
Table 1 Demographic data, prevalence of metabolic risk factors, complications and characteristics of liver function at
time of initial HCC diagnosis
Characteristics NASH - HCC Non-NASH - HCC P
(n = 45) (n = 1074)
Male gender* 35 (77.8) 888 (82.7) 0.820
Age at time of diagnosis# 67.6 (46.6-89.9) 65 (15.3-87.3) 0.007
Caucasian* 45 (100) 1055 (98.2) 1,000
Obesity* 13 (28.9) 158 (14.7) 0.046
BMI (kg/m2)# 29 (19.4-49.6) 26.6 (16.5-48.4) 0.022
Type II diabetes * 30 (66.7) 406 (37.8) 0.024
Hypertension* 32 (71.1) 485 (45.2) 0.060
Hyperlipidemia* 18 (40) 211 (19.6) 0.016
Myocardial infarction* 6 (13.3) 52 (4.8) 0.035
apoplectic stroke* 4 (8.9) 23 (2.1) 0.025
Cirrhosis* 35 (77.8) 858 (79.9) 1,000
Child-Turcotte-Pugh-Score*
A 21 (46.7) 421 (39.2) 0.577
B 14 (31.1) 301 (28) 0.748
C 0 136 (12.7) 0.012
Bilirubin# 0.8 (0.3-4.8) 1.2 (0.2-78.3) <0.001
INR# 1.1 (0.8-1.4) 1.1 (0.9-3.2) <0.001
Creatinine# 1 (0.6-7.5) 0.9 (0.3-7.2) 0.420
Albumin# 35 (19–52.6) 34 (3–55.6) 0.173
Thrombocytopenia* 15 (33.3) 472 (43.9) 0.394
AFP# 96.9 (1.5-96611) 39 (0–624094.4) 0.722
MELD score# 9 (6–21) 10 (6–40) 0.005
Encephalopathy* 0 44 (4,1) 1.640
Ascites* 14 (31.1) 235 (21.9) 0.299
Varices* 10 (22.2) 342 (31.8) 0.420
Portal vein thrombosis* 13 (28.9) 222 (20.7) 0.290
*Data presented in (n [%]); #Data presented in (median [range]); Bilirubin (normal range <1 mg/dL), Albumin (normal range 34–48 g/l, platelets count (normal
range 150-450/nL), AFP (normal range <8 ng/mL). A p value p<0.05 was considered significant and is marked in bold.
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(n = 4) vs. 2.1% (n = 23), p = 0.025) was significantly higher
in patients with NASH-HCC (Table 1). Prevalence of
metabolic risk factors and complications according to the
underlying aetiology of HCC are displayed in Table 2.Preserved hepatic function in NASH-HCC
Hepatic function in patients with NASH and non-
NASH-HCC at the time of initial diagnosis are summa-
rized and compared in Table 1. In contrast to the reports
in the literature, there was a similar rate of cirrhosis in
both groups (77.8% in NASH patients vs. 79.9%), with
21.2% of all HCCs developing in non-cirrhotic liver [16].
Patients with NASH-HCC exhibited a better hepatic func-
tion at the time of diagnosis. Correspondingly, the MELD
score (median [range]: 9 [6–21] vs. 10 [6–40], p = 0.005),
levels of bilirubin and INR were significantly lower in
NASH-HCC. Regarding Child-Turcotte-Pugh Score (CTP)
there was a lower rate of CTP stage C (p = 0.012) in
NASH-HCC and a significant difference in platelet counts
(NASH vs. non-NASH-HCC: 215/nl vs. 152/nl, p = 0.017).
No differences with regards to ascites, portal vein throm-
bosis, oesophageal varices, presence of encephalopathy or
levels of alpha-fetoprotein (AFP) at the time of diagnosis
were observed.HCC characteristics in NASH and non-NASH origin
Histological confirmation of HCC was obtained in 87.1% of
all patients. Tumour grading by the Edmondson-Steiner
classification and BCLC tumour stages were comparable
between NASH-HCC and HCC of other aetiology (Table 3).
In NASH-HCC tumour size at the time of initial diagnosis
exhibited a trend towards larger size compared to non-
NASH-HCC (median [range]: 6 cm [1.5-16.5] vs. 4.8 cm
[0–28], p = 0,176). Although no statistically relevant differ-
ences with regards to multifocal tumour spread was ob-
served, this occurred in 80% of NASH-HCC and only in
69.7% of the non-NASH-HCC group. No difference was
present with regard to lymph node metastasis while thereTable 2 Prevalence of metabolic risk factors and complications
according to the underlying aetiology of HCC
Characteristic NASH Alcohol HBV HCV
(n = 45) (n = 405) (n = 135) (n = 254)
Obesity 13 (28.9) 86 (21.2) 12 (8.9) 21 (8.3)
Typ II diabetes 30 (66.7) 200 (49.4) 39 (28.9) 66 (26)
Hypertension 32 (71.1) 200 (49.4) 57 (42.2) 96 (37.8)
Hyperlipidemia 18 (40) 92 (22.7) 28 (20.7) 45 (17.7)
Myocardial infarction 6 (13.3) 25 (6.2) 4 (3) 10 (3.9)
Apoplectic stroke 4 (8.9) 9 (2.2) 3 (2.2) 0 (0)
Thrombocytopenia 15 (33.3) 198 (48.9) 61 (45.2) 148 (58.3)
Data presented in (n [%]); platelets count (normal range 150-450/nL).was a trend towards more distant metastases in NASH-
HCC.
Differences in treatment and overall survival in NASH and
non-NASH-HCC
Primary therapy and overall survival (OS) are listed in
Table 3. The most common treatment of HCC was
transarterial chemoembolization (TACE) in both groups.
No patient in the NASH-HCC group underwent ortho-
tropic liver transplantation (OLT) as primary treatment
while 4% of patients with non-NASH-HCC were trans-
planted. OLT following bridging therapy with TACE was
performed in 4.4% of NASH and in 17.5% of non-
NASH-HCC patients. Systemic therapy with sorafenib as
a first line treatment was significantly more frequently
performed in NASH-HCC (17.8% vs. 3.5%, p < 0.001).
The median survival of all patients was 15.3 months
(range 0–131 months). Notably overall survival (OS) in
NASH-HCC was 4.22 months shorter compared to non-
NASH-HCC (median [range]: 11.28 [0.7-127.6] vs. 15.5
[0–131.3], p = 0.287) (Figure 2). In HCC, OS is strongly
depended on liver function. Imn the absence of cirrhosis,
NASH-HCC patients showed a trend to an increased OS
compared to non-NASH HCC patients (43.4 vs. 25 month,
p = 0.748) (Figure 2). Both, compensated cirrhosis (CTP
stage A) and decompensated cirrhosis (CTP stage B and
C) were associated with a decreased survival in NASH-
HCC compared to non-NASH-HCC. Patients with NASH-
HCC in CTP stage A exhibited a decreased in OS (15.5 vs.
24.2 months, p = 0.268). The difference in OS in CTP
stage B reached statistical significance (5.55 vs. 10.6 month,
p < 0.05). In this clinical cohort there were no NASH-
HCC patients with CTP stage C (Figure 2). A second fac-
tor that was identified to contribute to the OS in these
patients was BMI. A higher BMI was associated with lon-
ger survival in all groups of HCC even independent of the
underlying aetiology (Figure 2).
Discussion
NAFLD – beeing the most prevalent liver disease in in-
dustrialized countries – can lead to NASH, where the
emergence of HCC – even in the absence of cirrhosis –
has been described [1]. Among all patients with NAFLD,
the third leading cause of death is related to liver-specific
causes [17] and HCC contributes significantly to this mor-
tality [18]. Still, the underlying pathomechanism, the asso-
ciated risk factors and incidence of NASH-HCC are
poorly understood. In the current retrospective analysis,
epidemiology, risk factors, tumour characteristics, therapy
and overall survival in patients with NASH-HCC were
evaluated in a large single-centre cohort consisting of
1119 HCC patients in Germany, which represents one of
the most comprehensive cohorts in Germany [19]. In ac-
cordance to the literature, patients with NASH-HCC were
Table 3 Tumour characteristics and treatment in NASH vs non-NASH-HCC
Characteristics NASH - HCC Non-NASH - HCC P
(n = 45) (n = 1074)
(n [%]) (n [%])
Histological confirmation of HCC 39 (86.7) 939 (87.4) 1.000
Grading
G1 9 (20) 233 (21.7) 1.000
G2 20 (44.4) 438 (40.8) 0.781
G3 6 (13.3) 162 (15.1) 1.000
Median tumour size (cm)# 6 (1.5-16.5) 4.8 (0–28) 0.176
Metastases at initial diagnosis
Lymph nodes 2 (4.4) 62 (5.8) 1.000
Distant 5 (11.1) 87 (8.1) 0.423
Morphology
solitaire 9 (20) 319 (29.7) 0.324
multifocal 36 (80) 749 (69.7) 0.565
no data 0 6 (0.6) 1.000
BCLC at HCC diagnosis
BCLC A 9 (20) 258 (24) 0.727
BCLC B 11 (24.4) 179 (16.7) 0.248
BCLC C 19 (42.2) 458 (42.6) 1.000
BCLC D 6 (13.3) 173 (16.1) 0.836
no data 0 6 (0.6) 1.000
UICC
I 7 (15.6) 278 (25.9) 0.290
II 11 (24.4) 320 (29.8) 0.629
III 22 (48.9) 374 (34.8) 0.203
VI 0 0 1.000
Primary therapy
Resection 8 (17.8) 213 (19.8) 1.000
OLT 0 43 (4) 0.407
OLT after bridging 2 (4.4) 188 (17.5) 0.054
TACE 19 (42.2) 503 (46.8) 0.785
RFA/PEI 2 (4.4) 55 (5.1) 1.000
Chemotherapy 1 (2.2) 22 (2) 0.615
Sorafenib 8 (17.8) 38 (3.5) <0.001
Best supportive care 3 (6.7) 120 (11.2) 0.619
Overall survival (months)# 11.28 (0.7-127.6) 15.5 (0–131.3) 0.287
#Data presented in (median [range]). A p value p<0.05 was considered significant and is marked in bold.
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[7]. However, the predominance of male gender com-
monly observed in HCC was less pronounced in the
NASH-HCC group [20].
Since the definition of NASH-HCC included metabolic
risk factors, the frequency of metabolic features and the
frequency of obesity (BMI > 30 kg/m2) were significantly
higher in this group. Recent studies have shown that abody mass index above 30 kg/m2 and the presence of
type 2 diabetes are associated with an increased risk of
HCC development [21,22]. In our analysis the preva-
lence of type 2 diabetes mellitus was almost two fold
higher in NASH-HCC, comparable to the findings of
Davila et al. [23]. Likewise, the prevalence of hyperten-
sion, as a common co-morbidity, was increased in
NASH-HCC and a significant higher rate of myocardial
Figure 2 Kaplan-Meier survival curves. Kaplan-Meier survival curves comparing overall survival in NASH-HCC and non-NASH-HCC patients; A for
all patients; B for all patients regarding presence of liver cirrhosis; C for all patients with Child Pugh stage A; D for all patients with Child Pugh
stage B; E for all patients regarding obesity; F for NASH-HCC and non-NASH-HCC patients regarding obesity.
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NASH-HCC patients.
Recent studies showed an increasing number of pa-
tients with NASH-associated HCC in comparison to
other underlying aetiologies and it has been suggested
that NASH may become the most frequent cause of
HCC in an era with improving therapeutic options for
chronic viral hepatitis [1]. In the current analysis alco-
holic liver disease (36%) was the most frequent cause of
HCC, comparable to other investigations in Germany
[24,25]. Interestingly, NASH-HCC accounted for only
4% of all HCC cases. The frequency of NASH-related
HCC is likely influenced by the retrospective analysis
which excluded all patients with any reported alcohol
consumption. Thus this analysis likely excludes patients
with NASH and a regular but low consumption of alco-
holic beverages. Additionally, NASH as a cofactor in
other underlying disease was not considered in this ana-
lysis. Several studies suggested that undiagnosed NASH
is existent in patients with idiopathic or cryptogenic cir-
rhosis [2,7]. In the current cohort, cryptogenic cirrhosis
accounted for 17% of cases, in analogy to findings in the
literature, where a range between 6.9 up to 50% has been
described in industrialized countries [7]. The prevalence
of cryptogenic cirrhosis is clearly related to the quality
of the data acquisition and handling and is also a poten-
tial confounder.
Superior hepatic function in NASH-HCC patients
compared to other HCC is among the most relevant
findings of the current analysis. Although there was no
difference with regards to the prevalence of hepatic cir-
rhosis, more NASH-HCC patients presented in early
CTP stage A or B and the MELD score was significantly
lower. The difference between the two groups regarding
the absolute MELD score with 9 vs. 10 seems low, but
with regard to the range, the highest MELD score in
NASH-HCC patients was 21 while in the other group it
was 40. These findings are in accordance with data in
the United States that found a lower MELD score in
NASH-HCC patients [20].
The majority of HCC in this cohort was confirmed by
histology. Although EASL and AASLD guidelines do not
require a biopsy for diagnosis, these were frequently ob-
tained following patient consent to (1) differentiate re-
generative nodules from HCC and (2) to develop and
identify prognostic marker. Thus we were able to assess
tumour grading, where no significant difference between
the two groups was observed. Interestingly, HCC was
larger in the NASH-HCC group and we observed a
trend towards multifocality and a higher rate of distant
metastases at the time of diagnosis. In the literature,
NASH-HCC has been typically described as large and
well-differentiated at the time of presentation [7]. In
HCC, curative treatment is only available in early stages,in which liver transplantation or resection is feasible. In
the current analysis liver transplantation was not per-
formed as primary therapy in any of the 45 cases of
NASH-HCC. This might be related to the tendency of
NASH-HCC to have a larger tumour size and a higher
rate of multifocality at the time of diagnosis, possibly
restricting surgical therapy. As discussed above, hepatic
function was significantly better in these patients, and
thus it is conceivable that the detection of cirrhosis and its
complications were delayed. Other studies have made
similar observations and suggested that NASH-related
HCC may be diagnosed at a later time point and more ad-
vanced stage [26]. The differences in hepatic function also
influenced the decision to initiate systemic treatment with
sorafenib, which was significantly more frequently applied
as primary treatment in our NASH-HCC patients. Sorafe-
nib and transarterial chemoembolization are currently the
only non-curative treatments that improve survival [27].
The results regarding the overall survival in NASH-
HCC are inconsistent. In a recent study the overall sur-
vival following curative treatment approaches for HCC
was increased in NASH compared to patients with HCV
and/or alcoholic liver disease [20]. Wong et al. found
that patients with NASH in the absence of HCC exhib-
ited a better survival following OLT compared to pa-
tients with HCV or HCC of non-NASH origin [28],
while Dyson and colleagues reported similar survival of
NAFLD and other aetiologies for HCC [29]. In the
current cohort, overall survival was shorter in NASH-
HCC and a significant difference existed in the subgroup
of patients with CTP B. It can be speculated that this de-
crease in survival is related to a delay in detection of the
disease. Alternatively, these differences could be ex-
plained by different treatment strategies, since systemic
therapy with sorafenib is currently only recommended
for CTP A. Other explanations include the existence of
co-morbidities and the higher age in NASH-associated
HCC. A second central observation with regards to
overall survival was the differences in patients with a
higher BMI, which was protective. These observations
are in contrast to several other studies, which reported a
negative correlation of BMI and mortality in HCC
[30,31]. Limitations of this analysis are related to the
retrospective nature of the clinical cohort. Also, follow-
up data regarding the cause of death was not completed
available. In cases with complete death records mortality
was related to complications of the underlying liver dis-
ease and tumour progression, rather than co-morbidities
or cardiovascular disease.
Conclusions
In conclusion, despite the growing prevalence of NASH,
the frequency of NASH-HCC in a retrospectively de-
rived European cohort between 2000 and 2010 is low.
Weinmann et al. BMC Cancer  (2015) 15:210 Page 8 of 9Nonetheless, metabolic risk factors are highly prevalent
in these patients and a further increase is expected due
to the strong association with obesity and diabetes [32].
Thus, screening efforts in NASH have to be intensified
to avoid diagnosis at a late stage which excludes curative
treatment options and exhibit a decrease in survival.
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